SPX-101 (Sparx Therapeutics)

N/A

Report date: 2024/11/02 20:00:07

Base Information

Drug NameSPX-101 (Sparx Therapeutics)
Drug Alias NameSX-001KY-71113KY71113SPX-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CLDN18Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumoursStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesKpc Pharmaceuticals IncSparx Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSparx Therapeutics IncKpc Pharmaceuticals Inc
Inactive CompaniesKeba Biological (Jiangsu) Co Ltd
Active IndicationsStomach Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A